Company profile

Xuanzhu Biopharmaceutical

2575 · HKEX

Public Market Listing

2575HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Xuanzhu Biopharmaceutical are available on Yahoo Finance.

External market data link · No third-party exchange redistribution

Assets

(4 total)

4Total Assets

0Approved

2Phase 3 / Filed

2Phase 1–2 / Early

2Diseases

Showing 4 of 4 assets

		Target & Modality
XZP-3287	Phase 3	CDK4/6Small molecule	Breast Cancer HR+/HER2- Metastatic Breast Cancer
XZP-3621	Phase 3	ALK / ROS1Small molecule	Non-Small Cell Lung Cancer
XZP-5955	Phase 1/2	ROS1/NTRKSmall molecule	Non-Small Cell Lung Cancer
XZB-0004	Phase 1	AXL inhibitorSmall molecule	Non-Small Cell Lung Cancer

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.